Back to search results

Finerenone vs. Torsemide/Spironolactone for Hypertension and Chronic Kidney Disease

This study is comparing two different treatments for people with high blood pressure (hypertension) and chronic kidney disease (CKD). One treatment is a combination of two drugs, extended-release torsemide and spironolactone. The other treatment is finerenone, along with a loop diuretic like furosemide. Researchers want to see which treatment provides a better overall clinical benefit, looking at how much it lowers blood pressure, reduces protein in the urine (UACR), and affects potassium levels in the blood. You may be able to join if you are an adult aged 18 or older, have CKD with specific kidney function (eGFR) and protein levels, and have high blood pressure. The study plans to enroll 30 participants, but its current status is unclear.

Study design
This is a randomized study comparing two different treatment groups. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main effects of the treatments will be measured at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07223502

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

Recruiting
PHASE3Ages 18+InterventionalTreatment
Sarfez Pharmaceuticals, Inc.
~30 participants
Updated 2026-03-09 on ClinicalTrials.gov
What's tested:Combination Product: FDC of spironolactone and ER torsemideCombination Product: Stabilized doses of loop diuretic and finerenone

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with SBP reduction
Measured over 12 weeks
+2 more outcomes measured

Conditions

Hypertension (HTN)

Explore related trials

Chronic Kidney DiseaseHypertension

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Chris Wilcox, MD, PhD · STUDY_DIRECTOR · Sarfez Pharmaceuticals, Inc.

Who to contact

Salim Shah, PhD, JD
[email protected]
877-872-7339
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with SBP reduction12 weeks

    SBP ≥10 mmHg reduction from baseline (binary: yes/no).

  • Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with UACR reduction12 weeks

    NCB is defined as UACR ≥30% reduction from baseline (binary: yes/no).

  • Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with Serum K⁺ reduction12 weeks

    Serum K⁺ ≤5.0 mmol/L at end of treatment (binary: y/no)